department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

LEVETIRACETAM · pharmadog

pharmadog
drugs
LEVETIRACETAM

drug

patient view →

LEVETIRACETAM

Marketedupdated 2mo ago

by UCB SA

Approved

community read0 votes

indications

investigational

Epilepsy

all catalysts(1)

approval · 1

LEVETIRACETAM — FDA approval

News(0)

no news has mentioned this drug yet

brand

LEVETIRACETAM

generic

LEVETIRACETAM

indication

Myoclonic Seizure

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 3, 2027

~1.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (32)

Mar 14, 2034formulationUS 11160786
Mar 14, 2034formulationUS 11160786
Mar 14, 2034formulationUS 11160786
Mar 14, 2034formulationUS 11160786
Mar 14, 2034formulationUS 9339489
Mar 14, 2034formulationUS 9339489
Mar 14, 2034formulationUS 9339489
Mar 14, 2034formulationUS 9339489
Mar 14, 2034method-of-use (U-1850)US 9669009
Mar 14, 2034method-of-use (U-2021)US 9669009
Mar 14, 2034method-of-use (U-1850)US 9669009
Mar 14, 2034method-of-use (U-2022)US 9669009
Dec 7, 2031patentUS 8802142*PED
Dec 7, 2031patentUS 8802142*PED
Dec 7, 2031patentUS 8802142*PED
Dec 7, 2031patentUS 8802142*PED
Jun 7, 2031formulationUS 88021424.9y
Jun 7, 2031formulationUS 88021424.9y
Jun 7, 2031formulationUS 88021424.9y
Jun 7, 2031formulationUS 88021424.9y
Sep 17, 2028formulationUS 78581222.2y
Sep 17, 2028formulationUS 78581222.2y
Oct 31, 2027formulationUS 84311561.3y
Oct 31, 2027formulationUS 84311561.3y
Oct 31, 2027formulationUS 84703671.3y
Oct 31, 2027formulationUS 84703671.3y
Sep 3, 2027formulationUS 81633061.2y
Sep 3, 2027formulationUS 81633061.2y
Feb 22, 2026formulationUS 8425938
Feb 22, 2026formulationUS 8425938
Feb 22, 2026formulationUS 8535717
Feb 22, 2026formulationUS 8535717

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

tagApproval44 co-mentions · 22 sources
druglevetiracetam ER31 co-mentions · 23 sources
druglevetiracetam ODT31 co-mentions · 23 sources
tagSmall Molecule21 co-mentions · 21 sources
drugRNS-609 co-mentions · 1 sources
companyDr. Reddy's Laboratories Ltd6 co-mentions · 1 sources
companyGland Pharma Ltd3 co-mentions · 1 sources
tagRecall3 co-mentions · 1 sources

Trials studying LEVETIRACETAM

—Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infantsrecruitingn=1,600
phase2High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegalyrecruitingn=30
phase1Bioequivalence Study of Levetiracetam 1500 mg Coated Granules in Healthy, Male Subjectscompletedn=20
phase2rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Diseaseenrolling by invitationn=24
phase3A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsycompletedn=63
phase3A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)completedn=361
phase1Levetiracetam 1000 mg Under Fasting Conditionscompletedn=30
phase1Levetiracetam 1000 mg Under Non-Fasting Conditionscompletedn=22

more trials →